[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 1993

Cimetidine as Therapy for Treatment-Resistant Psoriasis in a Patient With Acquired Immunodeficiency Syndrome

Author Affiliations

USNR; USN, National Naval Medical Center, Bethesda, Md; USA; Walter Reed Army Institute of Research, Washington, DC; USN, Armed Forces Institute of Pathology, Washington, DC; Henry M. Jackson Foundation, Rockville, Md

Arch Dermatol. 1993;129(7):848-850. doi:10.1001/archderm.1993.01680280036005
Abstract

REPORT OF CASE  In January 1989, a 28-year-old black man severely affected with the acquired immunodeficiency syndrome developed diffuse psoriasiform lesions characterized by welldemarcated, erythematous plaques with adherent silvery scale, predominantly involving the trunk (Fig 1) and the extensor surfaces of the extremities. Punch biopsy was performed, and the specimen was stained with Leder stain (chloroacetate esterase) that showed regular acanthosis with clubbed rete ridges, confluent parakeratosis, and a perivascular infiltrate of lymphocytes and mast cells (Figs 2 and 3). The patient had no family history of psoriasis.In September 1989, a regimen of oral zidovudine (500 mg/d) and aerosolized pentamidine (300 mg/mo) was started. Throughout the course of his disease, these medications did not affect his psoriatic lesions. In the 18 months following the development of psoriasis, multiple topical medications including tar, anthralin, and potent corticosteroids were tried but did not result in improvement of the lesions.

THERAPEUTIC CHALLENGE 

First Page Preview View Large
First page PDF preview
First page PDF preview
×